Development of a mass spectrometry-enabled assay for the identification of new cellular targets for antibody-drug conjugates that utilize a novel payload delivery mechanism

免疫生物化学开发了一种颠覆性技术，将彻底改变抗体-药物结合(ADC)治疗领域。ADC是一类新型的靶向治疗药物，它结合了单抗的高度特异性和高效的化疗小分子药物，能够选择性和有效地将有毒有效载荷输送到癌细胞。免疫生物化学新一代肿瘤学ADC利用一种新的方法，能够基于细胞内肿瘤抗原或癌症生物标记物靶向实体肿瘤，这些肿瘤被认为是不可药物的，也无法获得靶向生物治疗。免疫生物化学领先的ADC，IMB-101和IMB-102，针对的是一种未披露的细胞内肿瘤抗原，这是一种经过临床验证的癌症生物标志物，与传统的受体靶向ADC相比，它对癌细胞具有更好的选择性。因此，IMB-101和IMB-102提供了卓越的安全性和广泛的治疗窗口，防止了许多ADC常见的对正常、健康细胞的靶向毒性，包括临床批准的ADC曲妥珠单抗DM1(Kadcyla®)。IMB-101和IMB-102正在为三阴性乳腺癌(TNBC)开发，TNBC是一种侵袭性疾病，目前还没有针对性的生物治疗选择。拟议的工作将使免疫生物化学能够利用质谱学和定量癌蛋白质组学方面的学术专业知识来开发和验证一种分析方法，以发现ADC疗法的新细胞靶点，从而利用免疫生物化学新的有效载荷传递机制。

ImmunoBiochem has developed a disruptive technology that will revolutionize the field of Antibody-Drug Conjugate (ADC) therapeutics. ADCs comprise a novel class of targeted therapeutics that combine the high specificity of monoclonal antibodies with highly-potent chemotherapeutic small-molecule drugs, and are able to selectively and efficaciously deliver a toxic payload to cancer cells. ImmunoBiochems next-generation ADCs for oncology utilize a novel approach that enables the targeting of solid tumors based on intracellular tumor antigens or cancer biomarkers that are considered undruggable and inaccessible to targeted biological therapeutics. ImmunoBiochems lead ADCs, IMB-101 and IMB-102, are targeted at an undisclosed intracellular tumor antigen that is a clinically-validated cancer biomarker, and offer superior selectivity for cancer cells compared to conventional receptor-targeted ADCs. IMB-101 and IMB-102 thus offer a superior safety profile and broad therapeutic window, preventing on-target toxicities against normal, healthy cells that are common with many ADCs, including the clinically approved ADC, trastuzumab DM1 (Kadcyla®). IMB-101 and IMB-102 are being developed for Triple-Negative Breast Cancer (TNBC), an aggressive disease for which no targeted biological therapeutic treatment options are currently available. The proposed work will enable ImmunoBiochem to leverage academic expertise in mass spectrometry and quantitative onco-proteomics to develop and validate an assay for the discovery of new cellular targets for ADC therapeutics that can take advantage of ImmunoBiochems new payload delivery mechanism.